Prazosin in the Treatment of Heart Failure: Problems and Potential

  • S. H. Taylor
Conference paper


The scientific rationale for the use of drugs which selectively block α-adrenoceptor antagonists in the treatment of heart failure has been convincingly expounded on a number of occasions (Braunwald 1977; Mason 1978; Taylor 1980) and repeatedly demonstrated in practice (see reviews by Taylor et al. 1982; Ribner et al. 1982; Franciosa 1983). But as with many therapies used in this dynamic circulatory situation, the results of such treatment have not lived up to the expectations (Taylor, 1983). The reasons are clear: Too much was asked of too little. This simplistic concept that modulation of one circulatory consequence of heart failure would fundamentally alter the haemodynamic profile, the symptom complex, the morbidity risk or the length of survival in this terminal pathophysiological state failed to take into account the powerful compensatory mechanisms still existing in these patients. But neither should the real clinical benefits and unproved potential of α-adrenoceptor modulation in this syndrome be totally discounted. The evidence must be carefully and sensibly sifted to determin what benefits are possible and how such therapy should be further explored. This is the attitude that will prevail in this brief review of prazosin in the treatment of heart failure.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bell D (1984) Prazosin in congestive heart failure: clinical experience from multi-site studies in the United States. In: Poole-Wilson PA (ed) Congestive heart failure symposium - prazosin in ambulatory patients with heart failure. Royal Society of Medicine, London (International Congress and Symposium Series, vol 63)Google Scholar
  2. Braunwald E (1977) Vasodilator therapy - a physiologic approach to the treatment of heart failure. N Engl J Med 297: 331PubMedCrossRefGoogle Scholar
  3. Colucci WS, Williams GH, Braunwald E (1980) Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Ann Intern Med 93: 452–453PubMedGoogle Scholar
  4. Corr PB, Yamada KA (1984) Pathophysiological mechanisms of alpha-adrenoceptor stimulation in the ischemic heart. In: Rietbrock N, Woodcock BG (eds) Balanced alpha/beta blockade of adrenoceptors. Vieweg, Braunschweig/Wiesbaden, pp 161–170Google Scholar
  5. Elkayam UE, LeJemtel TH, Mathur M et al. (1979) Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545PubMedCrossRefGoogle Scholar
  6. Franciosa JA (1982) Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure. Prog Cardiovasc Dis 24: 319–330PubMedCrossRefGoogle Scholar
  7. Lopez-Sendon J, Coma-Canella I, Lombera F et al. (1979) Use of oral prazosin hydrochloride in congestive heart failure following acute myocardial infarction. Am Heart J 98: 495–504PubMedCrossRefGoogle Scholar
  8. Majid PA, Sharma B, Taylor SH (1971) Phentolamine for vasodilator treatment of severe heart failure. Lancet II: 719–724CrossRefGoogle Scholar
  9. Mancini D, LeJemtel T, Sonnenblick E (1985) Intravenous use of amrinone for the treatment of the failing heart. Am J Cardiol 56(3) : 8B-15BPubMedCrossRefGoogle Scholar
  10. Mason DT (1978) Afterload reduction and cardiac performance. Am J Med 65: 106PubMedCrossRefGoogle Scholar
  11. Nelson GIC, Verma SP, Hussain M (1984) A randomised study of the haemodynamic changes induced by venodilatation and arteriolar dilatation singly and together in left ventricular failure complicating acute myocardial infarction. J Cardiovasc Pharmacol 6: 331–338PubMedCrossRefGoogle Scholar
  12. Ribner HS, Bresnahan D, Hsieh A-M et al. (1982) Acute hemodynamic responses to vasodilator therapy in congestive heart failure. Prog Cardiovasc Dis 25: 1–42PubMedCrossRefGoogle Scholar
  13. Schwartz KM, Urthaler F, James TN (1980) Direct effect of prazosin on the canine sinus node. Clin Res 28(5): 880AGoogle Scholar
  14. Scroop GC, Whelan RF (1966) A central vasomotor action of angiotensin in man. Clin Sci 30: 79–87PubMedGoogle Scholar
  15. Shell WE, Donald MA, Peter T et al. (1982) Comparison of clinical signs and haemodynamic state in the early hours of transmural myocardial infarction. Am Heart J 104: 521–528PubMedCrossRefGoogle Scholar
  16. Sheridan DJ, Penkoske PA, Sobel BE, Corr PB (1980) a-Adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest 65: 161–171PubMedCrossRefGoogle Scholar
  17. Silke B, Hendry WG, Taylor SH (1981a) Immediate and sustained haemodynamic effects of prazosin during upright exercise in man. Br Heart J 46: 663–670PubMedCrossRefGoogle Scholar
  18. Silke B, Lakhani ZM, Taylor SH (1981b) Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure. J Cardiovasc Pharmacol 3(2): 329–355PubMedCrossRefGoogle Scholar
  19. Taylor SH (1980) Vasodilator drugs in the treatment of heart failure. J Cardiovasc Pharmacol 2 [Suppl 3]: 407–424Google Scholar
  20. Taylor SH (1983) Promises and disappointments of vasodilator treatment of chronic heart failure. In: Just H, Bussmann W-D (eds) Vasodilators in chronic heart failure. Springer, Berlin Heidelberg New York, pp 93–111CrossRefGoogle Scholar
  21. Taylor SH (1985) Diuretics in cardiovascular therapy. Perusing the past, practising in the present, preparing for the future. Z Kardiologie 74 [Suppl 2]: 2–12Google Scholar
  22. Taylor SH, Silke B, Nelson GIC (1982) Principles of treatment of left ventricular failure. Eur Heart J 3 [Suppl D]: 19–43PubMedGoogle Scholar
  23. Taylor SH, Storstein L (1983) Diuretics and digitalis in the treatment of chronic heart failure. Eur Heart J 4 [Suppl A]: 153–159PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • S. H. Taylor
    • 1
  1. 1.Dept. of Medical CardiologyThe General InfirmaryLeesGreat Britain

Personalised recommendations